MRE11 and breast carcinoma: In basal-like breast cancer, MRE11 K673la improves DNA end resection and homologous recombination repair, conferring resistance to poly ADP-ribose polymerase inhibitors, olaparib, and cisplatin (Chen Y. et al., 2024).